In esophageal and colorectal tumors, the antitumor effect of MEDI3622 was superior to that of the EGFR/HER pathway inhibitor, suggesting that MEDI3622 inhibits tumor growth by partially modulating non-EGFR-mediated pathways (263). This evidence concerns the gene EGFR and colorectal neoplasm.